Kracov Quoted in InsideHealthPolicy on FDA's Biologics Naming Plan
May 10, 2019
Arnold & Porter partner Daniel Kracov, co-chair of the firm's Life Sciences and Healthcare Regulatory practice, was quoted in a recent InsideHealthPolicy article, "FDA Official 'Not A Fan Of,' But Sees Logic For, Biologics Naming Plan." In the article, Kracov explains why the agency's latest naming convention approach for new biological products and not already-approved therapies is necessary.
